Omrix Gets Acquired By J&J (OMRI, JNJ)

Health and Healthcare

Published: November 24, 2008 6:45 am

Last Updated: April 28, 2020 3:09 am

It looks as though not quite all the mergers are dead on the medical tech and biotechnology front. Johnson & Johnson (NYSE: JNJ) announced that it is acquiring Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI). The $438 million cash tender offer will pay $25.00 per share to Omrix holders.

Omrix is a fully integrated biopharmaceutical company that develops andmarkets biosurgical and immunotherapy products. It is expected tooperate as a stand-alone entity reporting through J&J’s ETHICON,Inc. unit, which is a provider of suture, mesh, hemostats and otherproducts for a wide range of surgical procedures.

The boards of directors of Johnson & Johnson and Omrix haveapproved the transaction. In addition, Robert Taub, Omrix’s Founder andChief Executive Officer, and entities controlled by Robert Taub, haveagreed to tender approximately 16% of Omrix’s outstanding shares in thetender offer. J&J sees an after tax charge of roughly $120 millionand expects this deal to close by the end of 2008.

Omrix closed at $21.16 on Friday, and its 52-week trading range is $8.99 to $38.18.

Jon C. Ogg
November 24, 2008

It’s Your Money, Your Future—Own It (sponsor)

Retirement can be daunting, but it doesn’t need to be.

Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter!

Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.